Aster DM Quality Care Q1 FY27: A merger goes live, and the numbers follow

Aster DM Quality Care Limited entered Q1 FY27 as two large hospital platforms operating side by side. It ended the quarter with a single legal entity. The merger became effective on 1 July 2026, and the first combined proforma quarter shows what the enlarged footprint can do when volumes rise and costs stay disciplined.

On a proforma basis, the merged entity reported Revenue from Operations of INR 2,597 Cr in Q1 FY27, up 20 percent year on year. Operating EBITDA rose 30 percent to INR 576 Cr, with margin expanding 170 bps to 22.2 percent. Patient volumes reached 2.01 Mn, up 13 percent, while ALOS improved to 3.40 days from 3.47 days. ROCE increased to 22.9 percent from 20.4 percent, reflecting both earnings growth and better asset utilisation.

The quarter also carried a clear execution message. Management framed the merger as completed on schedule with zero operational friction, covering 41 plus sites and aligning 4,000 plus key leaders on day one. For investors, this matters because integration can disrupt hospital operations quickly. Here, the early emphasis was on continuity of care, shared culture, and operational stability, which helps explain why growth drivers in the quarter remained centered on patient throughput, specialty mix, and cost management rather than one-off integration benefits.

What drove Q1: volumes, higher-end mix, and a stronger contribution from MVT

The combined narrative is consistent across both legacy platforms. Revenue growth was aided by steady patient volume expansion and a tilt towards higher-end tertiary procedures. The proforma ARPP increased 10 percent year on year to INR 1,36,802, driven by growth in complex care including robotic procedures, transplants, and joint replacements. Neurosciences, Oncology, Orthopedics, and Gastroenterology were cited as leading specialties for patient volume growth.

Another visible tailwind was Medical Value Travel. The merged entity reported MVT growth of 62 percent, supported by addition of new geographies. In the merged hospitals and clinics revenue mix, MVT contributes 4 percent of revenue in Q1 FY27 versus 3 percent in the prior year quarter. That base is still small, but the growth rate and the consistent mention across the presentation suggest MVT is being treated as a scalable, margin-supportive channel.

At the footprint level, the platform is now large enough to be described as one of the top three hospital chains in India, with 39 hospitals across 28 cities and 9 states, plus international presence. The company reported capacity beds of 10,898 and operational beds of 10,559 on a proforma basis in Q1 FY27, with occupancy at 64 percent for the merged entity.

Inside the combined performance: Aster and Quality Care both held their end

A useful feature of the presentation is that it does not treat the merger as a single blended story. It shows how each side performed in Q1 FY27, which helps investors gauge whether the combined growth is broad based.

Aster delivered 22 percent year on year revenue growth to INR 1,311 Cr in Q1 FY27 and operating EBITDA of INR 277 Cr, up 29 percent. Operating EBITDA margin improved to 21.1 percent from 20.0 percent. The company highlighted occupancy improvement by 350 bps to 62 percent, and ALOS improving to 3.0 days. ARPP IP rose 10 percent to INR 1,30,352 and total patient count rose 16 percent to 1.03 mn.

Quality Care reported Q1 FY27 revenue of INR 1,287 Cr, up 19 percent, and operating EBITDA of INR 299 Cr, up 32 percent. EBITDA margin expanded 216 bps to 23.2 percent and ROCE improved to 23.1 percent. Operational beds remained at 5,174, but total patients increased 10 percent to 0.98 mn. The quarter also featured a notable operational headline: occupancy improved by 656 bps to 65.4 percent. Management linked the improvement to higher IP volume growth, a better payor mix towards cash and insurance, and a higher share of complex procedures.

Two observations stand out from these side by side numbers. First, both businesses expanded margins while growing revenue at high teens to low twenties rates, indicating that cost absorption and mix were strong, not just volumes. Second, Quality Care entered the merger with higher margins, while Aster showed a strong ramp-up narrative through new capacity and faster maturity gains.

Scale is visible, but integration discipline and bed expansion will decide the compounding

Hospitals are not only about growth. They are also about ramp-up and maturity. In the maturity-wise performance view for Q1 FY27, mature units contributed 73 percent of revenue and 86 percent of operating EBITDA, with a 29.7 percent operating EBITDA margin. Focus units generated 15 percent of revenue with 16.8 percent margin. Emerging hospitals delivered 6 percent of revenue at 12.4 percent margin. Under performing units were 5 percent of revenue with 3.6 percent margin.

This mix matters because it shows where incremental margin can come from. The biggest immediate lever is not adding new hospitals, but lifting focus and under performing units towards mature thresholds. Management also highlighted examples of faster stabilisation. The newly operationalised Kasargod hospital achieved EBITDA breakeven in June within nine months of launch. That is a useful data point because new hospitals usually drag margins during ramp-up.

Expansion plans, however, remain material. The company outlined a planned addition of 4,179 beds to reach total capacity of 15,077 beds. The near-term plan includes 634 beds in FY27, followed by 1,190 in FY28 and 1,555 in FY29, with FY30 and beyond adding 800 beds. Importantly, 53 percent of the planned beds are in existing facilities and 47 percent in new facilities. For investors, this mix implies a meaningful brownfield component, which usually carries lower execution risk and faster payback than greenfield.

Alongside physical expansion, the integration thesis is framed through synergies. The presentation lists multiple avenues such as business KPI and reporting standardization, material cost optimization including pharmacy and consumables, capex efficiencies, indirect cost optimization through AMC and CMC, IT integration including call centre, CRM and digital app, and initiatives like F and B inspourcing and renewable energy savings. Management quantified the opportunity as a 10 to 15 percent EBITDA uplift, measured as a percent of FY24 proforma EBITDA of the merged entity.

That estimate should be read as directional, not guaranteed, but the underlying levers are typical for multi-site hospital operators. Procurement scale can lower material costs, IT integration can lift throughput and referral conversion, and standardized reporting can enable faster course correction at unit level. What is notable is the consistent focus on operational levers rather than purely financial engineering.

Clinical and brand positioning also remain central to the strategy. Q1 FY27 clinical highlights included advanced procedures such as transcatheter Fontan, robotic-assisted revision knee replacement using CORI system, and a large robotic hepatic artery infusion therapy program. The company also listed infrastructure at scale, including 58 cathlabs, 14 LINACs, 34 MRI machines, and 23 robots. These capabilities support the ARPP and case mix narrative seen in the quarter.

Investor takeaways: the platform is larger, execution is the differentiator

Q1 FY27 is best read as a proof point for operating momentum ahead of full financial consolidation. On a proforma basis, the merged entity delivered 20 percent revenue growth and 30 percent operating EBITDA growth, with margin expansion to 22.2 percent and ROCE rising to 22.9 percent. Patient volumes grew 13 percent, ALOS improved, and occupancy for the merged network reached 64 percent.

The merger, effective 1 July 2026, is positioned as operationally smooth and culturally structured, with leadership alignment and enterprise-wide rollout completed without service disruption. That matters because the next phase will be about capturing synergies while executing a multi-year bed expansion plan that targets 15,077 capacity beds.

For investors, the quarter’s theme is disciplined execution at scale. If the company can keep ramp-ups short, lift weaker units through standardization and procurement benefits, and sustain tertiary mix growth and MVT momentum, the combined platform has a clear route to compounding earnings and improving return metrics. The first proforma quarter does not prove the full synergy story, but it shows the base business is already moving in the right direction.